RxDoctor Payments Data

Behzad Molavi, MD

Interventional Cardiology · Brighton, CONPI 1306936885

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $36,767 of the $48,207 with a category attached, or 76.3%. 60 manufacturers reported payments, led by Medtronic at 29.3% of the total.

$48,207in general payments, 2019–2025

Across 1,037 payments — averaging $46.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$14K
  • Angiodynamics, Inc.$4K
  • Abbott$3K
  • Boston Scientific$2K
  • Cvrx, Inc.$2K
  • Biotronik Inc.$2K
  • plus $20K from 54 others
$37,259in research payments, 2019–2025

Across 2 payments — averaging $18,630 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$37K

What the payments were for

  • Travel & lodging$7,30715%
  • Food & beverage$36,76776%
  • Education$1,4183%
  • Other$2,7156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)166$14,116
Angiodynamics, Inc.11$4,476
Abbott47$3,069
Boston Scientific50$2,321
Cvrx, Inc.20$1,897
Biotronik Inc.24$1,828
Actelion Pharmaceuticals US, Inc.88$1,766
Shockwave Medical, Inc18$1,566
Philips North America LLC33$1,205
Johnson & Johnson61$988
Cardiovascular Systems Inc.12$867
E.r. Squibb & Sons, L.L.C.37$839
Inari Medical, Inc.24$800
Penumbra, Inc.7$799
Novartis36$778
Impulse Dynamics (USA) Inc.9$774
Bayer33$692
Amgen31$676
AstraZeneca33$651
Bard Peripheral Vascular, Inc.25$605
Heartflow, Inc.23$568
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)23$531
Sanofi-aventis U.S. LLC23$524
W. L. Gore & Associates, Inc.7$492
Kestra Medical Technology Services, Inc.15$466
Boehringer Ingelheim21$455
Novo Nordisk20$368
Pfizer16$357
Abiomed8$327
Endologix LLC4$269
Alnylam Pharmaceuticals Inc.9$262
Cagent Vascular Inc3$243
Terumo Medical Corporation2$214
Merck10$186
Esperion Therapeutics, Inc.10$176
Tactile Systems Technology Inc8$168
Smith+Nephew1$141
United Therapeutics Corporation5$130
ZOLL Respicardia, Inc.1$129
Amarin Pharma, Inc.6$124
Cardinal Health 200 LLC2$123
Cardiva Medical, Inc.3$117
Siemens Medical Solutions USA, Inc.1$91
Kiniksa Pharmaceuticals International, PLC4$78
Scpharmaceuticals Inc.4$70
Preventice Services, LLC2$67
Regeneron Healthcare Solutions, Inc.2$66
Daiichi Sankyo Inc.4$64
Veryan Medical Incorporated1$54
Venclose Inc.4$52
Kaneka Medical America LLC1$41
Arbor Pharmaceuticals, Inc.2$36
Lundbeck LLC2$36
Kiniksa Pharmaceuticals, Ltd.2$35
Ionis Pharmaceuticals, Inc.1$34
Lexicon Pharmaceuticals, Inc.2$30
Bridgebio Pharma, Inc.1$28
Ossur Americas, Inc.1$26
Asahi Intecc USA, Inc.1$25
Inspire Medical Systems, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,207 in reported general payments places this provider in the 80th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$362,440
Medicare patients
428
Services billed
2,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$250,074
FarxigaDapagliflozin Propanediol52$45,852
XareltoRivaroxaban42$44,759
BrilintaTicagrelor40$36,886
EntrestoSacubitril/Valsartan18$28,226
MultaqDronedarone Hcl11$14,636
Repatha SureclickEvolocumab20$13,182
Repatha SyringeEvolocumab18$11,934
Nebivolol Hcl34$3,168
Prasugrel Hcl25$2,243
ClopidogrelClopidogrel Bisulfate186$1,950
Ranolazine ErRanolazine23$1,834
Metoprolol Succinate106$1,610
Atorvastatin Calcium167$1,445
Flecainide Acetate12$1,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$357$250,074235 claims
AstraZenecaFarxiga, Brilinta$651$82,73792 claims
Johnson & JohnsonXarelto$988$44,75942 claims
NovartisEntresto$778$28,22618 claims
Sanofi-aventis U.S. LLCMultaq$524$14,63611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Brighton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →